MeiraGTx Holdings PLC ( MGTX ) Reports Q2 Loss, Beats Revenue Estimates
MeiraGTx (MGTX) delivered earnings and revenue surprises of +7.69% and +59.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Xilio Therapeutics, Inc. ( XLO ) Reports Q2 Loss, Misses Revenue Estimates
Xilio Therapeutics (XLO) delivered earnings and revenue surprises of -100.00% and -10.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
MeiraGTx Sales Jump 1,133 Percent
MeiraGTx Plc ( NASDAQ:MGTX ) , a biotechnology company specializing in gene therapies for neurodegenerative, ocular, and glandular disorders, released its second quarter results on August 14, 2025. The key news centered on a sizable year-over-year revenue gain ( GAAP ) -reflecting progress in ...
InflaRx N.V. ( IFRX ) Reports Q2 Loss, Misses Revenue Estimates
InflaRx (IFRX) delivered earnings and revenue surprises of 0.00% and -61.21%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
3 Promising Genomics Stocks to Keep an Eye On in 2025
Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases
Paris, France - May 21, 2025 - Coave Therapeutics ( 'Coave' ) , a company pioneering the future of genetic medicines, today announces the evolution of its Scientific Advisory Board ( SAB ) .
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday - Annexon ( NASDAQ:ANNX ) , Camtek ( NASDAQ:CAMT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. cut Annexon, Inc. ANNX price target from $20 to $14.
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy ( ASGCT ) 2025 Annual Meeting
Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx's Technology Platforms for Gene and Cell Therapy Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx's Technology Platforms for Gene and Cell Therapy ...
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy ( ASGCT ) 2025 Annual Meeting - MeiraGTx Hldgs ( NASDAQ:MGTX )
LONDON and NEW YORK, May 13, 2025 ( GLOBE NEWSWIRE ) -- MeiraGTx Holdings plc MGTX, a vertically integrated, clinical stage genetic medicines company, today announced the Company will exhibit four poster presentations at the American Society of Gene and Cell Therapy ( ASGCT ) 2025 Annual ...
MeiraGTx Holdings PLC ( MGTX ) Reports Q1 Loss, Misses Revenue Estimates
MeiraGTx (MGTX) delivered earnings and revenue surprises of -34.21% and 76.85%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy ( RMAT ) Designation for AAV-GAD for the Treatment of Parkinson's Disease
- This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease ...
Beam Therapeutics ( BEAM ) Moves 12.6% Higher: Will This Strength Last?
Beam Therapeutics (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
AnaptysBio ( ANAB ) Moves 9.5% Higher: Will This Strength Last?
AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Crude Oil Falls 1%; Dollar General Posts Upbeat Sales - Aveanna Healthcare Hldgs ( NASDAQ:AVAH ) , Aditxt ( NASDAQ:ADTX )
U.S. stocks traded lower midway through trading, with the S&P 500 falling more than 1% on Thursday. The Dow traded down 1.17% to 40,865.63 while the NASDAQ dipped 1.64% to 17,359.52. The S&P 500 also fell, dropping, 1.18% to 5,533.34. Materials shares gained by 0.9% on Thursday.
G-III Apparel Posts Better-Than-Expected Earnings, Joins Ballard Power Systems, Dollar General And Other Big Stocks Moving Higher On Thursday - Advantage Solutions ( NASDAQ:ADV ) , AES ( NYSE:AES )
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Thursday. Shares of G-III Apparel Group, Ltd. GIII gained 13.9% to $28.87 after the company reported better-than-expected fourth-quarter financial results and issued FY26 adjusted EPS guidance above estimates.
MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars - MeiraGTx Hldgs ( NASDAQ:MGTX )
MeiraGTx secures $200M upfront and a joint venture with Hologen, which will invest up to $230M to develop AAV-GAD for Parkinson's disease. MeiraGTx retains 30% ownership in Hologen Neuro AI Ltd, leading clinical development and manufacturing under exclusive supply agreements.
MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process - MeiraGTx Hldgs ( NASDAQ:MGTX )
- MeiraGTx to receive $200 million in upfront cash consideration - MeiraGTx and Hologen will form a joint venture, Hologen Neuro AI Ltd, with an additional $230 million committed capital from Hologen to fund 100% of the development of AAV-GAD for Parkinson's disease through to commercialization, ...
MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process
- MeiraGTx to receive $200 million in upfront cash consideration ...
MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 ( LCA4 ) Retinal Dystrophy
LONDON and NEW YORK, Feb. 21, 2025 ( GLOBE NEWSWIRE ) -- MeiraGTx Holdings plc ( Nasdaq: MGTX ) , a vertically integrated, clinical stage genetic medicines company, today announced the publication of results from the first-in-human interventional study to treat children with AIPL1-associated ...
MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations
MeiraGTx has recently received Rare Pediatric Disease Designation ( RPDD ) for four inherited retinal diseases ( IRDs ) reflecting the transformative therapeutic potential of the Company's proprietary technology platforms MeiraGTx has recently received Rare Pediatric Disease Designation ( RPDD ) ...
MeiraGTx Holdings PLC ( MGTX ) Reports Q3 Loss, Tops Revenue Estimates
MeiraGTx (MGTX) delivered earnings and revenue surprises of -14.89% and 4,264%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Jim Cramer: This Tech Stock Is A Buy, SoFi Technologies Is Good - Jabil ( NYSE:JBL )
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Jabil Inc. JBL, adding that it is "such a good company." On Sept. 26, Jabil reported better-than-expected fourth-quarter financial results and approved a $1 billion share buyback.
AMN Healthcare Services ( AMN ) Tops Q3 Earnings and Revenue Estimates
AMN Healthcare (AMN) delivered earnings and revenue surprises of 5.17% and 2.60%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Sanofi ( SNY ) Q3 2024 Earnings Call Transcript
SNY earnings call for the period ending September 30, 2024.
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study - Alnylam Pharmaceuticals ( NASDAQ:ALNY ) , ANI Pharmaceuticals ( NASDAQ:ANIP )
MeiraGTx Holdings' MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson's disease ( PD ) met its primary study objective of safety and tolerability. The stock soared 14.9% in response to the news.
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study
MeiraGTx stock rises 15% as gene therapy candidate betters sham treatment in Parkinson's disease patients.
MeiraGTx ( MGTX ) Surges 14.9%: Is This an Indication of Further Gains?
MeiraGTx (MGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results - Johnson & Johnson ( NYSE:JNJ )
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 150 points on Tuesday. The Dow traded down 0.30% to 42,937.44 while the NASDAQ fell 0.84% to 18,347.17. The S&P 500 also fell, dropping, 0.43% to 5,834.67. Real estate shares jumped by 2% on Tuesday.
Small Cap-MeiraGTx Reveals Encouraging Data From Parkinson's Study Showing Significant, Clinically Meaningful Changes in Key Efficacy Endpoints - MeiraGTx Hldgs ( NASDAQ:MGTX )
On Tuesday, MeiraGTx Holdings plc MGTX released topline data from its clinical bridging study of AAV-GAD for Parkinson's disease, MGT-GAD-025. MGT-GAD-025 is a 6-month, three-arm, randomized, double-blind, sham-controlled study using AAV-GAD drug product manufactured by MeiraGTx at its ...
Crude Oil Tumbles 5%; Goldman Sachs Earnings Top Views - Telefonaktiebolaget L M ( NASDAQ:ERIC ) , CareDx ( NASDAQ:CDNA )
U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 150 points on Tuesday. The Dow traded down 0.40% to 42,894.69 while the NASDAQ fell 0.93% to 18,331.05. The S&P 500 also fell, dropping, 0.44% to 5,833.93. Real estate shares jumped by 1.5% on Tuesday.
Walgreens Posts Upbeat Earnings, Joins Wolfspeed, Ericsson And Other Big Stocks Moving Higher On Tuesday - Walgreens Boots Alliance ( NASDAQ:WBA )
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Tuesday. Shares of Walgreens Boots Alliance, Inc. WBA rose sharply during Tuesday's session following better-than-expected quarterly earnings.
MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson's Disease - MeiraGTx Hldgs ( NASDAQ:MGTX )
The primary study objective of safety and tolerability was met Significant and clinically meaningful improvements from baseline demonstrated for key efficacy endpoints at 26 weeks Significant improvement of 18 points in Unified Parkinson's Disease Rating Scale ( UPDRS ) Part 3 in the high dose ...
MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference
Results indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiency Results indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiency ...
Harmony Biosciences ( HRMY ) Surges 6.7%: Is This an Indication of Further Gains?
Harmony Biosciences (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
MeiraGTx Holdings PLC Reports Q2 Loss, Lags Revenue Estimates - MeiraGTx Hldgs ( NASDAQ:MGTX ) , Mainz Biomed ( NASDAQ:MYNZ )
MeiraGTx Holdings PLC MGTX came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.53 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of ...
MeiraGTx Holdings PLC ( MGTX ) Reports Q2 Loss, Lags Revenue Estimates
MeiraGTx (MGTX) delivered earnings and revenue surprises of -145.16% and 98.28%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results
- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia ( RIX ) presented at the American Academy of Oral Medicine 2024 annual meeting ( AAOM ) showed meaningful improvements in patient-reported outcomes and saliva production with AAV2-hAQP1 treatment ...
MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi
LONDON and NEW YORK, Aug. 12, 2024 ( GLOBE NEWSWIRE ) -- MeiraGTx Holdings plc ( Nasdaq: MGTX ) , a vertically integrated, clinical stage genetic medicine company, today announced the pricing of an underwritten offering of 12,500,000 of its ordinary shares at an offering price of $4.00 per share.
Arbutus Biopharma ( ABUS ) Reports Q2 Loss, Tops Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of -10% and 12.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations - Ovid Therapeutics ( NASDAQ:OVID )
The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse events Secondary endpoint results indicate that the target pharmacokinetic profile was achieved at the targeted clinical dose, supporting once daily dosing
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
NEW YORK, July 01, 2024 ( GLOBE NEWSWIRE ) -- Ovid Therapeutics Inc. ( NASDAQ: OVID ) , a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, and Graviton Bioscience Corporation, a privately held clinical-stage biotechnology ...
Jim Cramer Calls This Healthcare Stock A 'Worthy Spec,' Recommends Avoiding Canada Goose - Canada Goose Hldgs ( NYSE:GOOS )
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Dutch Bros Inc. BROS. On May 7, Dutch Bros posted better-than-expected first-quarter financial results and raised its full-year revenue guidance. "The outlook is fabulous.
CRISPR Therapeutics AG ( CRSP ) Reports Q1 Loss, Misses Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of 12.27% and 93.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease ( STGD1 ) and Geographic Atrophy ( GA ) and Perspectives On Tinlarebant
Webinar, moderated by Cantor Fitzgerald, will be held on Monday, May 13, 2024, at 2:00 p.m. ET ...
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease ( STGD1 ) and Geographic Atrophy ( GA ) and Perspectives On Tinlarebant - Belite Bio ( NASDAQ:BLTE )
Webinar, moderated by Cantor Fitzgerald, will be held on Monday, May 13, 2024, at 2:00 p.m. ET Discussion will feature Dr. Michel Michaelides, leading expert in the field of inherited eye disease in adults and children SAN DIEGO, May 06, 2024 ( GLOBE NEWSWIRE ) -- Belite Bio, Inc.
MeiraGTx Holdings PLC ( MGTX ) Reports Q4 Loss, Misses Revenue Estimates
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -2.17% and 79.86%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
- Company aligned with FDA on requirements for ongoing Phase 2 AQUAx2 clinical trial for Grade 2/3 radiation-induced xerostomia to be considered pivotal supporting potential BLA filing ...
Praxis Precision Medicines, Inc. ( PRAX ) Reports Q4 Loss, Tops Revenue Estimates
Praxis Precision Medicines, Inc. (PRAX) delivered earnings and revenue surprises of 5.71% and 71.67%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Lifecore Biomedical ( LFCR ) : Can Its 16.0% Jump Turn into More Strength?
Lifecore Biomedical (LFCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Wall Street Analysts Think MeiraGTx Holdings PLC ( MGTX ) Could Surge 217.92%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 217.9% in MeiraGTx Holdings PLC (MGTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
